Friday, April 15, 2016

In Pursuit of Slaves


Captain John Gabriel Stedman (1744-1797) was a professional soldier who fought to suppress an 18th-century slave rebellion in Suriname and subsequently published the March Through a Swamp in Pursuit of Slaves. Although slavery was not abolished in Suriname until 1873, the publication of Stedman’s narrative in 1790 helped to erode public support for the slave trade in Europe and its colonies. The book was translated into several languages and published in more than 25 editions. Stedman’s descriptions of the brutality of plantation life debunked the myth that slavery was a benign, civilizing influence. By his own admission, Stedman was a mercenary, who also told the truth, and his narrative endures as a case study of violence and human rights abuses. To counter the argument that slaves were better off on New World plantations than living under comparatively primitive conditions in their native lands, Stedman storied that in the Maroon rebellion the slaves preferred to endure hardships and fight in order to escape get their freedom.
JAMA. 2015;314(5):434-435

Friday, April 1, 2016

Stent versus surgery in carotid stenosis

In a study published in NEJM Rosenfield et al report the findings of a trial that compared carotid artery stenting with “embolic protection” to carotid endarterectomy.

In this trial, the authors compared carotid-artery stenting with “embolic protection” and carotid endarterectomy in 1453 patients who were 79 years of age or younger who had severe carotid stenosis and were asymptomatic.  Patients were followed for up to 5 years. The primary composite end point of death, stroke, or myocardial infarction within 30 days after the procedure or ipsilateral stroke within 1 year was tested at a non-inferiority margin of 3 percentage points.

The rate of stroke or death within 30 days was 2.9% in the stenting group and 1.7% in the endarterectomy group (P=0.33). From 30 days to 5 years after the procedure, the rate of freedom from ipsilateral stroke was 97.8% in the stenting group and 97.3% in the endarterectomy group (P=0.51), and the overall survival rates were 87.1% and 89.4%, respectively (P=0.21). The cumulative 5-year rate of stroke-free survival was 93.1% in the stenting group and 94.7% in the endarterectomy group (P=0.44).

The authors concluded that stenting was not inferior to endarterectomy with regard to the rate of the primary composite end point at 1 year. In analyses that included up to 5 years of follow-up, there were no significant differences between the study groups in the rates of non–procedure-related stroke, all stroke, and survival.


N Engl J Med 2016; 374:1011-1020

Saturday, March 12, 2016

Digital breast tomosynthesis may reduce recall rates

JAMA Oncology published McDonald et al research regarding the efficacy of digital breast tomosynthesis (DBT) on recall rates versus that of digital mammography (DM), and also its sustainability over the long term.

The study was a retrospective analysis of a total of 44468 screening events performed on 23958 women whose average age was 56 years and were followed over a period of 4 years.

Recall rates rose slightly for years 1 to 3 of DBT (88, 90, and 92 per 1000 screened, respectively) but remained significantly reduced compared with the DM zero rate of 104 per 1000 screened. The cancer cases per recalled patients continued to rise from DM zero rate of 4.4% to 6.2% for years 1 to 3 of DBT, respectively. Outcomes assessed for the most recent screening for individual women undergoing only 1, 2, or 3 DBT screenings during the study period demonstrated decreasing recall rates of 130, 78, and 59 per 1000 screened, respectively (P < .001). Interval cancer rates, determined using available follow-up data, decreased from 0.7 per 100 women screened with the use of DM to 0.5 per 1000 screened with the use of DBT.


Digital breast tomosynthesis screening outcomes are sustainable, with significant recall reduction, increasing cancer cases per recalled patients, and a decline in interval cancers.

Tuesday, March 1, 2016

USPSTF breast cancer screening guidelines

The United States Preventative Services Task Force (USPSTF) issued new guidelines for when and how often women should be screened for breast cancer.

The USPSTF recommends biennial screening mammography for women 50-74 years.  Women of average risk between the ages of 40 and 49 should make an individual choice about whether to initiate screening every other year.  The UUPSTF recommends against teaching self-breast examination.
       

The USPSTF’s recommendations are similar to those issued recently by the American Cancer Society.  ACR recommends initiation of annual screening at age 45 and transition to biennial at age 55 as long as a woman has life expectancy of 10 years or longer.

Sunday, February 14, 2016

Early diagnosis of ovarian cancer may reduce mortality

A study published by Jacobs et al in Lancet reports on a new approach for earlier diagnosis of ovarian cancer which is known for its poor prognosis. Their strategy was based on a series of CA125 tests, identifying women to be given ultrasound by a mathematical formula that took into account a woman’s age and the degree of change in CA125 over time, and calculated a risk score. In this randomized controlled trial, postmenopausal women aged 50–74 years from Great Britain were assigned to annual multimodal screening (MMS) with serum CA125, annual trans-vaginal ultrasound screening (USS), or no screening, in a 1:1:2 ratio. The primary outcome was death due to ovarian cancer, comparing MMS and USS separately with no screening. Between June 1, 2001, and Oct 21, 2005, 202 638 women were randomly allocated: 50 640 to MMS, 50 639 to USS, and 101 359 to no screening. Screening ended on Dec 31, 2011, and included 345 570 MMS and 327 775 USS annual screening episodes. At a median follow-up of 11·1 years, ovarian cancer was found in 1282 (0·6%) women: 338 (0·7%) in the MMS group, 314 (0·6%) in the USS group, and 630 (0·6%) in the no screening group. Of these women, 148 (0·29%) women in the MMS group, 154 (0·30%) in the USS group, and 347 (0·34%) in the no screening group had died of ovarian cancer. The primary analysis using a Cox proportional hazards model gave a mortality reduction over years 0–14 of 15% with MMS and 11% with USS. Although the mortality reduction was not significant in the primary analysis, the authors noted a significant mortality reduction with MMS when prevalent cases were excluded. They also noted encouraging evidence of a mortality reduction in years 7–14, but further follow-up is needed before firm conclusions can be reached on the efficacy and cost-effectiveness of ovarian cancer screening as 641 women had to be screened annually for 14 years for each life saved.

Monday, February 1, 2016

Elderly undergo cancer-screening tests that may not be necessary

Abdollah et al report in a JAMA Oncology article their findings that suggest some older individuals undergo screening tests for breast and prostate cancer despite the fact that those tests aren’t recommended for them.

The investigators looked at data from 149 514 individuals, 65 years or older selected among those who responded to the Behavioral Risk Factors Surveillance System Survey and resided in the United States. The primary outcome was non-recommended screening, defined as receipt of prostate-specific antigen (PSA) testing or mammography in individuals with a life expectancy of less than 10 years.

Of the 149 514 individuals, 76 419 (51.1%) had a PSA test or mammography in the past year; 23 532 (30.8%) of those individuals had a life expectancy of less than 10 years, corresponding to an overall rate of non-recommended screening of 15.7% (23 532 of 149 514 individuals).

Significant state-by-state variation in the rate of non-recommended screening was observed. Moreover, non-recommended screening at the state-by-state level had a correlation of 40% between the 2 forms of screening (P = .01). Therefore, a state with a high rate of non-recommended screening for prostate cancer is likely to have a high rate of non-recommended screening for breast cancer and vice versa.  The extent and variation of non-recommended screening across states, fluctuated from 11.6% in Colorado to 20.2% in Georgia.

The authors suggest that efforts should be made to reduce non-recommended screening as such scheme may reduce harms to individuals from false positives, and decrease the cost to the US health system from overdiagnosis that may be as high as $1.2 billion annually therefore improve the overall efficiency of screening initiatives.


Editor’s note:  The authors maybe are underestimating the cost to the US health system.  According to the US census individuals over 65 were 14.5% in 2014.   This percentage corresponds to 46 million in a total population of 318 million.  If we consider that the cost of mammography is $120 and of the PSA blood test $80 then the cost to the US health system could be as high as 4.6 billion dollars annually.